

**Adrian Shea Ishkanian, MSc, MD**

1. Date: 2/14/2017

**I. Personal**

2. Name: Adrian Shea Ishkanian, MSc, MD

3. Office Phone: 305-243-4210

4. Current Academic Rank: Assistant Professor

5. Primary Department: Radiation Oncology

6. Secondary Department: Cancer Biology (Instructor)

**II. Higher Education**

**7. Institutional:**

|     |   |            |
|-----|---|------------|
| MD  | University of British Columbia, Vancouver, BC Canada                | 2002-2006  |
| MSc | University of British Columbia, (Pathology and Laboratory Medicine) | 1998- 2001 |
| BA  | Cornell University Ithaca, NY (Biology)                             | 1993-1997  |

**8. Non-Institutional:**

|  |           |
|--|-----------|
| Fellowship, Radiation Oncology<br>Sunnybrook Hospital<br>University of Toronto, Toronto, ON Canada | 2011-2012 |
|--|-----------|

|  |           |
|--|-----------|
| Chief Resident<br>Department of Radiation Oncology<br>Princess Margaret Hospital | 2009-2010 |
|--|-----------|

|  |           |
|--|-----------|
| Residency, Radiation Oncology<br>University of Toronto<br>Toronto, ON Canada | 2006-2011 |
|--|-----------|

**9. Certification and licensure:**

Certification:

|  |           |
|--|-----------|
| Royal College of Physicians and Surgeons of Canada | 6/30/2011 |
|--|-----------|

(Radiation Oncology)

Licensure:

|  |           |
|--|-----------|
| College of Physicians and Surgeons of Canada | 6/30/2011 |
| Florida Board of Medicine                    | 2/10/2017 |

**III. Experience**

**10. Academic:**

|  |              |
|--|--------------|
| Assistant Professor, Miller School of Medicine<br>Sylvester Comprehensive Cancer Center,<br>University of Miami, Miami, FL | 2012-present |
|--|--------------|

**11. Hospital appointments:**

|  |               |
|--|---------------|
| Sylvester Comprehensive Cancer Center, Miami, Florida    | 2012- present |
| University of Miami Hospital and Clinics, Miami, Florida | 2012- present |
| Jackson Memorial Medical Center, Miami, Florida          | 2012- present |
| Lennar Foundation Medical Center, Miami, Florida         | 2016-present  |

**12. Non-Academic:**

|  |                    |
|--|--------------------|
| Project Coordinator, Array CGH Facility<br>British Columbia Cancer, Research Center<br>Vancouver, BC | 6/1/2002-6/31/2004 |
|--|--------------------|

|  |                    |
|--|--------------------|
| Clinical Fellow,<br>Radiation Oncology<br>Odette Cancer Center | 7/1/2011-8/31/2012 |
|--|--------------------|

**13. Military: N/A**

## IV. Publications

### 14. Books and monographs:

N/A

### 15. Juried or refereed journal articles or exhibitions:

1. Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, **Ishkanian A**. Radiation-induced VEGF-targeted 4-1BB costimulation enhances immune control of tumor growth. *Cancer Res* 2017 Jan 12. pii: canres.2105.2016. doi: 10.1158/0008-5472.CAN-16-2105 [Epub ahead of print]
2. Benaduce AP, Brenneman R, Schrand B, Pollack A, Gilboa E, **Ishkanian A**. 4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1; 96(2):458-61.
3. Stoyanova R, Pollack A, Takhar M, Lynne C, Parra N, Lam LL, Alshalafa M, Buerki C, Castillo R, Jorda M, Ashab HA, Kryvenko ON, Punnen S, Perekh DJ, Abramowitz MC, Gilles RJ, Davicioni E, Erho N, **Ishkanian A**. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. *Oncotarget* 2016 Aug 16;7(33):53362-53376.
4. Diaz DA, Pollack A, Reis IM, Mahmoud O, Gonzalgo ML, **Ishkanian A**, Fernandez G, Manoharan M, Abramowitz MC. Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis. *Clin Genitourin Cancer* 2015 Aug;13(4):378-384.
5. Lalonde E, **Ishkanian AS**, Sykes J, Fraser M, Erho N, Moon NC, Zafarana G, Meng A, Thoms J, Grzadkowski M, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Ahmed O, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Neal D, Pintilie M, Pra AD, Davicioni E, Lam WL, Milosevic M, Van der Kwast T, Boutros PC, Bristow R. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncol* Co-First Author (authors contributed equally) 2014 Dec; 15(13):1521-32.
6. Berlin A, Lalonde E, Sykes J, Zafarana G, Chu KC, Ramnarine VR, **Ishkanian A**, Sendorek DH, Pasic I, Lam WL, Jurisica I, van der Kwast T, Milosevic M, Boutros PC, Bristow RG. NBN Gain is Predictive for Adverse Outcome Following ImageGuided Radiotherapy for Localized Prostate Cancer. *Oncotarget* 2014 Nov 30;5(22):11081-90.
7. Dal Pra A, Lalonde E, Sykes J, Warde F, **Ishkanian A**, Meng A, Malloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG. TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. *Clin Cancer Res* 2013 Sep 15;19(18):5202-9.

8. McKee CM, Xu D, Cao Y, Kabraji S, Allen D, Kersemans V, Beech J, Smart S, Hamdy F, **Ishkanian A**, Sykes J, Pintile M, Milosevic M, van der Kwast T, Zafarana G, Ramnarine VR, Jurisica I, Malloff C, Lam W, Bristow RG, Muschel RJ. Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. *J Clin Invest* 2012 Nov;122(11):4025-36.
9. Milosevic M, Warde P, Catton C, Menard C, **Ishkanian AS**, Toi A, Bristow R, Chung P, Sykes J, Gospodarowicz M, Hill R, Bristow RG. Tumor Hypoxia Predicts Biochemical Failure Following Radiotherapy for Clinically Localized Prostate Cancer. *Clin Cancer Res*. 2012 Apr 1; 18(7):2108-14.
10. Zafarana G, **Ishkanian AS**, Malloff C, Locke J, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine V, Meng A, Ahmed O, Jurisica I, Milosevic M, Pintilie M, van der Kwast T, Bristow RG. Copy Number Alterations of c-MYC and PTEN are prognostic factors for relapse following prostate cancer radiotherapy. *Cancer*. 2012 Aug 15; 118(16):4053-62.
11. Locke JA, Zafarana G, **Ishkanian AS**, Milosevic M, Thoms J, Have CL, Malloff C, Lam WL, Squire J, Pintilie M, Sykes J, Ramnarine VR, Meng A, Ahmed O, Jurisica I, van der Kwast T, Bristow RG. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. *Clin Cancer Res*. Jan 1; 18(1):308-16, 2012
12. **Ishkanian AS**, Laperriere NJ, Xu W, Millar BA, Menard C, Payne D, Mason W, Sahgal A. Upfront observation versus radiation for adult pilocytic astrocytoma. *Cancer* 2011 Sep 1;117(17):4070-9.
13. **Ishkanian AS**, Zafarana G, Thoms J, Bristow RG. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. *Acta Oncol*. 2010 Oct;49(7):888-94.
14. **Ishkanian AS**, Malloff C, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire J, Lam WL, Bristow RG. High Resolution Array CGH Identifies Novel Regions of Genomic Alteration in Intermediate-Risk Prostate Cancer. *Prostate*. Jul 1; 69(10):1091-100, 2009.
15. Kuzak N, **Ishkanian AS**, Riyad A-L. Posterior Sternoclavicular Dislocation: Case Report and Discussion. *CJEM*. Sep; 8(5):355, 2006.
16. Garnis C, Coe B, Henderson LJ, **Ishkanian AS**, Watson S, Marra M, Minna J, Lam S, MacAulay C, Lam W. Construction and optimization of chromosome arm-specific comparative genomic hybridization arrays for identifying genetic alterations in preinvasive lung cancers. *Chest* 2004 May; 125(5 Suppl):104S-5S.
17. **Ishkanian AS**, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, Snijders A, Albertson DG, Pinkel D, Marra MA, Ling V, MacAulay C, Lam WL. A tiling resolution DNA microarray with complete coverage of the human genome. *Nat Genet*. 2004 Mar; 36(3):299-303.
18. Watson SK, DeLeeuw RJ, **Ishkanian AS**, Malloff CA, Lam WL. Methods for high throughput validation of amplified fragment pools of BAC DNA for constructing high resolution CGH arrays. *BMC Genomics* 2004 Jan 14; 5(1):6.

19. Garnis C, Coe BP, **Ishkanian AS**, Zhang L, Rosin MP, Lam WL. Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. *Genes Chromosomes Cancer* 2004 Jan; 39(1):93-8, 2004.
20. Siwoski A, **Ishkanian AS**, Garnis C, Zhang L, Rosin M, Lam WL. An efficient method for the assessment of DNA quality of archival microdissected specimens. *Mod Pathol.* 2002 Aug; 15(8):889-92.

#### 16. Other works, publications and abstracts:

1. Stoyanova R, Pollack A, Erho N, Lynne C, Lam L, Buerki C, Philip S, Jorda M, Kryvenko O, Abramowitz M, Davicioni E, **Ishkanian A**. Using Radiogenomics to Characterize MRI-Guided Prostate Cancer Biopsy Heterogeneity. Selected for Oral “Power Pitch” Presentation. ISMRM 23rd Annual Meeting & Exhibition. Toronto, ON. June, 2015.
2. Diaz Pardo DA, Abramowitz M, Mahmoud A, **Ishkanian A**, Fernandez J, Shields M, Manoharan A, Pollack A. Neoadjuvant Radiation Therapy Improves Survival in Patients with T2b/T3 Invasive Bladder Cancer. Poster Presentation. American Society for Radiation Oncology (ASTRO) Annual Meeting. San Diego, CA. September, 2013.
3. Abramowitz MC, Bossart E, Lachaine M, Brooks R, Lathuilere F, Freedman L, **Ishkanian AS**, Pollack A. Clinical Trial Comparison to RF Transponders with Visual Confirmation. Poster presentation. American Society for Radiation Oncology (ASTRO) Annual Meeting. Atlanta, GA. September, 2013.
4. **Ishkanian AS**, Zafarana G, Maloff C, Thoms J, Squire J, Pintile M, Milosevic M, Lam WL, van der Kwast T, Bristow RG. Genetic instability as measured by percent genome alteration (PGA) predicts for biochemical recurrence in localized prostate cancer following high-resolution array comparative genomic hybridization (arrayCGH). *Abstract and Poster Presentation*. International Cancer Genome Consortium Meeting. Australia. December, 2010.
5. Zafarana, G, **Ishkanian AS**, Maloff C, Thoms J, Squire J, Pintile M, Milosevic M, Lam WL, van der Kwast T, Bristow RG. Combined 8q gain and 10q loss predicts for relapse following radical radiotherapy in intermediate risk prostate cancer. *Abstract and Poster Presentation*. American Association of Cancer Research 101<sup>st</sup> Annual Meeting. Washington, DC USA. April, 2010.
6. **Ishkanian AS**, Malloff C, Ho J, Meng A, Albert M, Pintile M, van der Kwast T, Milosevic M, Lam WL, Bristow RG. Array CGH of prostate cancer biopsies identifies genetic variations in DNA damage sensing and repair pathways: implications for radiotherapy response. *Abstract and Poster Presentation*. International Wolfsberg Meeting on Molecular Radiation Biology/Oncology 2009. Ermatingen, Switzerland. June, 2009.
7. **Ishkanian AS**, Malloff C, Ho C, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire J, Lam WL, Bristow RG. High Resolution Array CGH of Intermediate-Risk Prostate Cancer Genomes. *Abstract and Poster Presentation*. American Society of Clinical Oncology. Chicago, IL USA. June, 2008.

8. Watson S, **Ishkanian AS**, Beheshti B, Squire JA, Lam WL. Characterization of copy number alterations in prostate cancer cell lines using a 77kb resolution whole genome DNA microarray by comparative genomic hybridization. *Abstract and Poster Presentation*. Annual Meeting of the American Association for Cancer Research, Orlando, FL USA. March, 2004.
9. Beheshti B, Vukovic B, Hughes S, Watson S, **Ishkanian AS**, Lam WL, Squire JA. High resolution genomic analysis of prostate cancer using CGH arrays and molecular cytogenetic methods. *Abstract and Poster Presentation*. Annual Meeting of the American Association for Cancer Research, Orlando, FL USA. March, 2004.
10. Henderson LJ, **Ishkanian AS**, Coe B, Garnis C, Marra M, Minna J, Lam S, MacAulay C, Lam WL. Identification of regions of DNA alteration on chromosome arm 1p in NSCLC and SCLC. *Abstract and Poster Presentation*. 10<sup>th</sup> World Conference on Lung Cancer. Vancouver, BC. August, 2003.
11. Coe B, Garnis C, **Ishkanian AS**, Malloff C, Watson S, Marra M, Lam S, MacAulay C, Minna J, Lam WL. Fine mapping of breakpoints of genetic alterations on chromosome 3p in lung cancer by array CGH. *Abstract and Poster Presentation*. 10<sup>th</sup> World Conference on Lung Cancer. Vancouver, BC. August, 2003.
12. **Ishkanian AS**, Rosin MP, Zhang L, Lam WL. One and two-dimensional fingerprinting identifies five novel regions frequently altered in oral premalignancies and tumors. *Abstract and Poster Presentation*. Annual Meeting of the American Association for Cancer Research, New Orleans, LA USA. March, 2001.
13. Ma S, **Ishkanian AS**, Siwoski E, Bainbridge T, Lam WL, Vielkind J. Optimization of Integrity and Yield of DNA Extracted From Laser Capture Microdissected Cells From Prostate and Breast Archival Biopsies. *Abstract and Poster Presentation*. National Institute of Health Symposium on Laser Capture Microdissection and Macromolecular Analysis of Normal Development and Pathology. Washington, DC USA. June, 2000.
14. **Ishkanian AS**, Rosin MP, Zhang L, Lam WL. Scanning for Genomic Alterations in Minute Premalignant Specimens. *Abstract and Poster Presentation*. Annual Meeting of the American Association for Cancer Research, San Francisco, CA USA. April 1999.
15. **Ishkanian AS**, Zhang L, Rosin MP, Lam WL. Novel Genetic Alterations in Oral Dysplasias and Tumors. *Abstract and Poster Presentation*. Annual Meeting of the American Association for Cancer Research, San Francisco, CA USA. April 1999.

### **Patents**

16. Lam W, Macaulay C, Watson S, **Ishkanian A**, Krzywinski M, Marra M. Methods for preparation of a library of submegabase resolution tiling pools and uses thereof. International Patent Publication No. WO 2004/111267. World Intellectual Property Organization International Bureau. 2004.

**17. Other works accepted for publication:**

N/A

**V. Professional**

**18. Funded research performed:**

Active Grant Funding:

Padron Family Private Donation 1/09/2015-present  
Role: Principal Investigator  
Title: Development of an epitope specific, cross-species reactive aptamer using next generation sequencing. Amount: \$100,000 Indirect Costs

NIH/NCI: R01CA190105 9/19/2014-8/31/2018  
Principal Investigator; Dr. Alan Pollack  
Role: Co-Investigator (5%)  
Title: (PQC-4) Habitats in Prostate Cancer.  
Amount: \$2,223,797 Direct Costs, \$2,773,731 Total Costs

NIH/NCI: R01CA189295 8/1/2014-7/31/2019  
Principal Investigator; Dr. Alan Pollack  
Role: Co-Investigator (4%)  
Title: MRI Imaging and Genetic Signatures to Manage Prostate Cancer Over-Diagnosis. Amount: \$2,511,346 Direct Costs, \$3,017,627 Total Costs

NIH/NCI: R01CA163370 7/09/2012-4/30/2018  
Principal Investigator; Dr. Ivaylo Mihaylov  
Role: Investigator (2%)  
Title: Improving Cancer Treatment Planning by DMH-Based Inverse Optimization. Amount: \$1,254,860 Direct Costs, \$1,926,210 Total Costs

Completed Grant Funding:

Stanley J. Glaser Foundation Research Award, 6/1/2014-5/31/2015  
University of Miami Miller School of Medicine  
Role: Principal Investigator  
Title: Immunotherapeutic strategies to enhance the efficacy of ionizing radiation for cancer therapy. Amount: \$40,000 Indirect Costs

Florida Prostate Cancer Research Consortium 6/1/2013-5/31/2014  
Role: Co-Investigator (no percent assigned)  
Title: Multi-Institutional Multi-Modality Modelling of High Risk Prostate Cancer. Amount: \$30,000 Indirect Costs

Florida Prostate Cancer Research Consortium 6/1/2013-5/31/2014  
Role: Co-Investigator (no percentage assigned)  
Title: Biomarker-assisted Nomogram for predicting aggressiveness of prostate cancer among racial and ethnic groups. Amount: \$30,000 (indirect)

Canadian Urologic Oncology Group (CUOG) Research Award 6/1/2008-5/31/2009  
Role: Principal Investigator  
Title: Identification of candidate predictive biomarkers specific to intermediate risk prostate cancer, which may aid in prognostication and prediction of individual response to therapy. Amount: \$10,000 (Indirect)

**19. Editorial responsibilities:**

Radiation Research. Expert reviewer. GU Malignancies 6/1/2014-present

International Journal of Radiation Oncology Biology Physics. 12/10/2012-present  
Expert reviewer: GU/Molecular Biology

**20. Professional and honorary organizations:**

Radiological Society of North America (RSNA) 2015-present

Radiation Therapy Oncology Group (RTOG/NRG) 2012-present

Sylvester Comprehensive Cancer Center 2012-present

Canadian Association of Radiation Oncology 2016-present

Sheila and David Fuente Graduate Program in Cancer Biology 2014-present

American Society for Therapeutic Radiology and Oncology (ASTRO) 2012-present

Ontario Medical Association 2002-present

**21. Honors and awards:**

American Radium Society Travel Grant. 5/2/2012  
American Radium Society's 94<sup>th</sup> Annual Meeting.  
Las Vegas, Nevada.

Best Resident Oral Presentation 10/3/2009  
Canadian Association of Radiation Oncology (CARO) Annual Scientific Meeting



|   |                     |
|---|---------------------|
| Award for Overall Excellence in Radiation Research by a Post Graduate Trainee.<br>Princess Margaret Hospital, Department of Radiation Oncology        | 6/30/2009           |
| W.J. Simpson Award for Excellence in Research by a Resident<br>Princess Margaret Hospital, Department of Radiation Oncology                           | 6/30/2009           |
| W.J. Simpson award for Excellence in Research by a Resident<br>Princess Margaret Hospital, Department of Radiation Oncology                           | 6/30/2008           |
| Award for Overall Excellence in Radiation Research by a Post Graduate Trainee<br>Princess Margaret Hospital, Department of Radiation Oncology         | 6/30/2008           |
| Novartis Oncology Young Canadian Investigator Award<br>American Society of Clinical Oncology Annual Meeting   | 6/01/2008           |
| Natural Sciences and Engineering Research Council of Canada.<br>(NSERC) PGS B scholarship. Department of Pathology.<br>University of British Columbia | 9/1/2000-8/31/2001  |
| Killam Undergraduate Scholarship. Cornell University  | 6/1/1995-5/31/1996  |
| Rix Studentship. Department of Pathology.<br>University of British Columbia   | 5/31/1999-5/30/2000 |
| Li Tze Fong Memorial Fellowship<br>Department of Pathology. University of British Columbia  | 9/1/2000-8/31/2001  |

## 22. Post-doctoral fellowships:

N/A

## 23. Other professional activities:

1. Schrand B, Benaduce AP, Gilboa E, **Ishkanian A**. Radiation Induced Tumor Targeting of Immunomodulatory Aptamers Induces Abscopal Response and Tumor Control in Murine Models of Breast Cancer. American Society for Radiation Oncology (ASTRO). Oral Presentation, September 28, 2016 Boston MA.
2. Brenneman R, Sullivan EJ, Berezhnoy A, Ishkanian F, Gilboa A, **Ishkanian A**. 4-1BB Aptamer-Based Immunomodulation Enhances the Efficacy of Ionizing Radiation in a Preclinical Murine Tumor Model. *Int J Rad Onc Biol Phys* S176;Sept 1, 2014. American Society for Radiation Oncology (ASTRO) Oral Presentation.
3. **Ishkanian AS**, Pollack A, Abramowitz M. Why Extreme Hypofractionation Obviates the Need for Androgen Deprivation in Intermediate Risk Prostate Cancer: A Proposed Model. 2<sup>nd</sup> Annual Florida Prostate Cancer Research Symposium. *Oral Presentation*. March 22, 2013. Orlando, FL.

4. **Ishkanian AS**, Malloff C, Ho J, Meng A, Albert M, Pintile M, Zafarana G, van der Kwast T, Milosevic M, Lam WL, Bristow RG. Global genetic instability as a predictor for outcome in intermediate risk prostate cancer. *Oral Presentation*. American Radium Society's 94th Annual Meeting. Las Vegas, Nevada. May, 2012.
5. **Ishkanian AS**, Malloff C, Ho J, Meng A, Albert M, Pintile M, Zafarana G, van der Kwast T, Milosevic M, Lam WL, Bristow RG. DNA copy number alterations independently predict for biochemical recurrence following radiotherapy in intermediate risk prostate cancer. *Oral Presentation: Clinical Trials*. American Society of Therapeutic Radiology and Oncology, Annual Meeting, San Diego, California, USA. October, 2010.
6. **Ishkanian AS**, Malloff C, Ho J, Meng A, Albert M, Pintile M, van der Kwast T, Milosevic M, Lam WL, Bristow RG. Copy number alteration predicts for biochemical recurrence in intermediate risk prostate cancer using high-resolution array comparative genomic hybridization. *Oral Presentation Winner*. Canadian Association of Radiation Oncology. 23<sup>rd</sup> Annual Scientific Meeting. Quebec City, QC. Canada. October, 2009.
7. **Ishkanian AS**. High-resolution array CGH of intermediate-risk prostate cancer genomes. Novartis Oncology Young Canadian Investigator Award Oral Presentation. American Society of Clinical Oncology. Chicago, IL. June, 2008.
8. **Ishkanian AS**, Watson S, Malloff C, Coe B, DeLeeuw R, Krzywinski M, Marra M, MacAulay C, Lam WL. Construction of a DNA microarray with complete coverage of the human genome. *Oral Presentation*. 10<sup>th</sup> World Conference on Lung Cancer. Vancouver, BC. August 2003.

## VI. Teaching

### 24. Teaching awards received:

N/A

### 25. Teaching specialization:

Invited Lecture: Updates on Radiation Oncology in Lung Cancer from ASTRO 2014. Community Oncology Education Dinner Series 10/22/2014

Instructor: Sheila and David Fuente Graduate Program in Cancer Biology Prostate Cancer: Biomarkers and Targets. 3/7/2014- present

Co-director/Primary Instructor: Radiation and Cancer Biology Lecture Series for Radiation Oncology Residents. University of Miami, Sylvester Comprehensive Cancer Center 8/1/2012-7/31/2014

Resident and Fellow Lectures: Yearly lectures on prostate, Bladder, Testis tumors. University of Miami, Miller School of Medicine 9/1/2012-present

Invited Lecture: Testicular Cancer 2/7/2012  
Department of Urology .University of Miami, Miller School of Medicine

**26. Thesis and dissertation advising/Post-doctoral student supervision:**

Post-Doctoral Supervisor: 1/5/2015-present  
Ana Paula Benaduce, PhD, University of Miami  
Department of Radiation Oncology  
Title of Project: Development of novel targeting radiation inducible ligands  
for therapeutic monoclonal antibody delivery in solid tumors.

Post-Doctoral Supervisor: 6/1/2013-6/1/2015  
Randall Brenneman, PhD, University of Miami.  
Department of Immunology.  
Title of Project: the use of oligonucleotide aptamers as radiotherapy adjuvants.

**VII. Service**

**27. University committee and administrative responsibilities:**

Grant Panel Member: 2/6/2015-present  
University of Miami, Sylvester Comprehensive Cancer Center  
Clinical and Translational Science Institute

Grant Panel Member: 2/6/2014-present  
University of Miami, Sylvester Comprehensive Cancer Center  
Acceleration Grant Panel Reviewer

UMMG Leadership Council Member for Radiation Oncology 6/1/2013-present

Grant Panel Member: 3/8/2013-3/1/2015  
Prostate Cancer Canada Discovery Grants  
Yearly Reviewer: Toronto, Ontario, Canada

New Investigator Representative: Translational Research 6/13/2013-/12/2014  
Program. Radiation Therapy Oncology Group (RTOG).

Department of Radiation Oncology Princess Margaret Hospital. 6/1/2009-5/31/2010  
Chief Resident

Department of Radiation Oncology  
Princess Margaret Hospital Resident  
Representative  
Academic Communications Committee 6/1/2009-5/31/2010

Department of Radiation Oncology Princess  
Margaret Hospital  
Resident Representative  
Post-Graduate Research Sub-Committee 6/1/2009-5/31/2010

**28. Community activities:**  
Woman’s Cancer Association Invited Speaker 08/12/2014  
Title: The Future of Radio-Immunotherapy in Breast Cancer  
Therapy

Woman’s Cancer Association Invited Judge 03/24/2015  
WCA Annual Bark Off